Categories Earnings, Health Care

Allergan beats estimates on Q1 results, raises full-year guidance

Allergan plc (NYSE: AGN) topped market forecasts on revenue and earnings for the first quarter of 2019. Despite the beat, shares fell 0.5% in premarket hours on Tuesday.

Total revenue decreased 2% year-over-year to $3.60 billion. The company’s core business grew 4.4% year-over-year across its four key therapeutic areas, helped by growth of products such as BOTOX Cosmetic, BOTOX Therapeutic, VRAYLAR, JUVEDERM and Lo LOESTRIN.

Allergan reports first quarter 2019 earnings

GAAP net loss attributable to ordinary shareholders was $2.4 billion, or $7.25 per share, versus $332.5 million, or $0.99 per share, in the year-ago period. Adjusted EPS grew 1.3% to $3.79.

In US Specialized Therapeutics, revenues decreased 2.3% year-over-year to $1.54 billion due to lower revenues in CoolSculpting and RESTASIS as well as the divestiture of the Medical Dermatology business, which offset the demand growth in BOTOX and JUVEDERM.

US General Medicine revenues grew 2.1% to $1.25 billion, primarily due to growth in VRAYLAR and Lo LOESTRIN. International revenues grew 1.3% to $801.5 million, due to growth in Facial Aesthetics.

Also see: Allergan Q1 2019 Earnings Conference Call Transcript

Allergan raised its outlook for the full year of 2019, and now expects GAAP net revenues to be in the range of $15.12 billion to $15.42 billion. Adjusted revenues are expected to be $15.10 billion to $15.40 billion. GAAP loss is expected to be $5.70 per share while adjusted EPS is expected to be $16.55.

For the second quarter of 2019, GAAP revenues are expected to be $3.87 billion to $4.02 billion. Adjusted revenues are expected to be $3.85 billion to $4.00 billion. GAAP EPS is expected to come in the range of $0.50-0.70 while adjusted EPS is expected to be $4.20-4.40.

 

Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Key highlights from CarMax (KMX) Q2 2023 earnings results

CarMax, Inc. (NYSE:KMX) reported second quarter 2023 earnings results today. Net revenues rose 2% year-over-year to $8.1 billion. Net earnings were $125.9 million, or $0.79 per share, compared to $285.2 million,

Should you buy Domino’s Pizza (DPZ) stock ahead of Q3 earnings?

The fast-food industry is among the worst affected by the inflation-induced dip in consumer confidence, which is weighing on the demand for discretionary items. Domino’s Pizza, Inc.  (NYSE: DPZ) is

Infographic: Key highlights from Paychex (PAYX) Q1 2023 earnings results

Paychex Inc. (NASDAQ: PAYX) reported first quarter 2023 earnings results today. Total revenue rose 11% year-over-year to $1.20 billion. Net income grew 14% to $379.2 million, or $1.05 per share,

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top